Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597777107> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2597777107 abstract "2556 Background: Volasertib (V) is a potent and selective cell cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinases. Nintedanib (N) is a triple angiokinase inhibitor of VEGF, PDGF, and FGF receptors. Both have shown clinical activity with a manageable safety profile in patients (pts) with advanced solid tumors. This study was designed to determine the maximum tolerated dose (MTD) of V combined with N in these pts. Methods: Cohorts of 3–6 pts received V (100–450 mg IV Q3W) + oral standard dose N (200 mg BID continuously, except V infusion day). Treatment continued until clinical progression. Up to 12 pts were treated at the MTD for additional safety data. Primary endpoint was the MTD; secondary endpoints were pharmacokinetics (PK), overall safety, and preliminary efficacy. Results: 30 pts were treated (median age, 56.5 yr; ECOG PS 0/1/2, 33%/60%/7%; ≥3 prior therapies, 87%). At V doses >200 mg, 7 pts experienced 13 dose-limiting toxicities (DLTs) during cycle 1: increased alanine aminotransferase [ALT] or aspartate aminotransferase [AST], neutropenia and thrombocytopenia. The MTD was V 300 mg (Table). At the MTD, the most common all grade (Gr) adverse events (AEs) were neutropenia (69%), asthenia and thrombocytopenia (62% each), increased ALT, increased AST and diarrhea (54% each). Median (range) duration on treatment was 4 (1–18) cycles. Treatment was discontinued due to progressive disease (80%), DLT (3%) and other non-AE related reasons (17%). 2 objective responses were observed (1 complete [breast cancer] and 1 partial [NSCLC]), both with the 300 mg dose. 6 pts had SD for ≥ 6 mo. PK data will be presented at the meeting. Conclusions: MTD of V + standard dose N (200 mg BID) was determined to be 300 mg Q3W (the same as the recommended phase II single agent dose of V in solid tumors). This combination had a manageable safety profile without unexpected or overlapping toxicities and showed preliminary antitumor activity. Clinical trial information: NCT01022853. [Table: see text]" @default.
- W2597777107 created "2017-04-07" @default.
- W2597777107 creator A5000664504 @default.
- W2597777107 creator A5006012404 @default.
- W2597777107 creator A5020982369 @default.
- W2597777107 creator A5042028913 @default.
- W2597777107 creator A5046917184 @default.
- W2597777107 creator A5049741024 @default.
- W2597777107 creator A5062234802 @default.
- W2597777107 creator A5064646828 @default.
- W2597777107 date "2013-05-20" @default.
- W2597777107 modified "2023-10-18" @default.
- W2597777107 title "A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors." @default.
- W2597777107 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.2556" @default.
- W2597777107 hasPublicationYear "2013" @default.
- W2597777107 type Work @default.
- W2597777107 sameAs 2597777107 @default.
- W2597777107 citedByCount "4" @default.
- W2597777107 countsByYear W25977771072014 @default.
- W2597777107 countsByYear W25977771072019 @default.
- W2597777107 countsByYear W25977771072021 @default.
- W2597777107 crossrefType "journal-article" @default.
- W2597777107 hasAuthorship W2597777107A5000664504 @default.
- W2597777107 hasAuthorship W2597777107A5006012404 @default.
- W2597777107 hasAuthorship W2597777107A5020982369 @default.
- W2597777107 hasAuthorship W2597777107A5042028913 @default.
- W2597777107 hasAuthorship W2597777107A5046917184 @default.
- W2597777107 hasAuthorship W2597777107A5049741024 @default.
- W2597777107 hasAuthorship W2597777107A5062234802 @default.
- W2597777107 hasAuthorship W2597777107A5064646828 @default.
- W2597777107 hasConcept C126322002 @default.
- W2597777107 hasConcept C2777714996 @default.
- W2597777107 hasConcept C2778341716 @default.
- W2597777107 hasConcept C2780171596 @default.
- W2597777107 hasConcept C2989005 @default.
- W2597777107 hasConcept C71924100 @default.
- W2597777107 hasConcept C98274493 @default.
- W2597777107 hasConceptScore W2597777107C126322002 @default.
- W2597777107 hasConceptScore W2597777107C2777714996 @default.
- W2597777107 hasConceptScore W2597777107C2778341716 @default.
- W2597777107 hasConceptScore W2597777107C2780171596 @default.
- W2597777107 hasConceptScore W2597777107C2989005 @default.
- W2597777107 hasConceptScore W2597777107C71924100 @default.
- W2597777107 hasConceptScore W2597777107C98274493 @default.
- W2597777107 hasLocation W25977771071 @default.
- W2597777107 hasOpenAccess W2597777107 @default.
- W2597777107 hasPrimaryLocation W25977771071 @default.
- W2597777107 hasRelatedWork W1527852087 @default.
- W2597777107 hasRelatedWork W2047377282 @default.
- W2597777107 hasRelatedWork W2057734053 @default.
- W2597777107 hasRelatedWork W2082214446 @default.
- W2597777107 hasRelatedWork W2227096465 @default.
- W2597777107 hasRelatedWork W2242665894 @default.
- W2597777107 hasRelatedWork W2333597938 @default.
- W2597777107 hasRelatedWork W2521115478 @default.
- W2597777107 hasRelatedWork W2565656857 @default.
- W2597777107 hasRelatedWork W2589658719 @default.
- W2597777107 hasRelatedWork W2590628578 @default.
- W2597777107 hasRelatedWork W2591287814 @default.
- W2597777107 hasRelatedWork W2598962029 @default.
- W2597777107 hasRelatedWork W2603128670 @default.
- W2597777107 hasRelatedWork W2603418464 @default.
- W2597777107 hasRelatedWork W2753514542 @default.
- W2597777107 hasRelatedWork W2785563856 @default.
- W2597777107 hasRelatedWork W3011041064 @default.
- W2597777107 hasRelatedWork W3011322631 @default.
- W2597777107 hasRelatedWork W3110787060 @default.
- W2597777107 isParatext "false" @default.
- W2597777107 isRetracted "false" @default.
- W2597777107 magId "2597777107" @default.
- W2597777107 workType "article" @default.